Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Aust Fam Physician. 2006 Oct;35(10):801-3.

Bisphosphonates and osteonecrosis of the jaw.

Author information

  • 1Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia, and the Australian Dental Association, Australia.

Abstract

Recently an association between bisphosphonate use and a rare dental condition termed 'osteonecrosis of the jaw' (ONJ) has been reported. Patients with osteoporosis and Paget disease who take bisphosphonates have a significantly reduced risk of fracture and other skeletal complications. This represents significant health benefits, against which the small risk of ONJ needs to be considered. In patients with bone malignancy, the risk of ONJ needs to be balanced against the benefit of therapy on the underlying malignancy. There are still many uncertainties about this condition. This position paper seeks to summarise what is currently known about ONJ to provide information to medical practitioners and dental practitioners.

PMID:
17019456
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Australian Family Physician
    Loading ...
    Write to the Help Desk